Osteoporosis medications work to strengthen bones and prevent fractures. Bisphosphonates slow bone loss, calcium and vitamin D support bone building, and estrogen receptor modulators mimic estrogen's protective effects on bone. Understanding how each class works helps you use them safely and educate patients effectively.
Nurses play a central role in osteoporosis management. You'll assess risk factors, monitor for side effects, and teach patients about proper administration and lifestyle changes. Staying on top of bone density testing and lab values helps patients maintain bone strength and avoid fractures.
Mechanisms of Action and Indications
Bisphosphonates, calcium, vitamin D, estrogen receptor modulators for osteoporosis
Bisphosphonates (alendronate, risedronate) work by inhibiting osteoclast activity, which are the cells responsible for breaking down bone. They bind to hydroxyapatite crystals in bone tissue and prevent dissolution, which reduces bone resorption and increases bone mineral density (BMD). Think of them as putting the brakes on bone breakdown rather than building new bone.
Calcium preparations (calcium carbonate, calcium citrate) provide the essential mineral your body needs for bone formation and maintenance. Calcium promotes mineralization of the bone matrix, directly supporting bone strength and density. Without adequate calcium, the body pulls it from existing bone, weakening the skeleton over time.
Vitamin D (cholecalciferol, calcitriol) does three things for bone health:
- Increases intestinal absorption of calcium and phosphate, making more mineral available for bone
- Stimulates osteoblast differentiation and activity, promoting new bone formation
- Regulates calcium and phosphate homeostasis, keeping levels in the range bones need
Cholecalciferol () is the inactive form that requires conversion in the liver and kidneys. Calcitriol is the active form, used when patients have kidney disease and can't convert on their own.
Estrogen receptor modulators (SERMs) selectively bind to estrogen receptors in bone tissue, mimicking estrogen's protective effects. They increase BMD by reducing bone resorption and supporting bone formation. Raloxifene is the primary SERM used for osteoporosis in postmenopausal women. An important distinction: raloxifene acts as an estrogen agonist in bone but as an antagonist in breast and uterine tissue, which is why it doesn't carry the same risks as hormone replacement therapy.
Adverse Reactions, Drug Interactions, and Patient Care
Indications, adverse reactions, drug interactions for osteoporosis medications
Bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid)
- Indications: Prevention and treatment of postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, and Paget's disease
- Adverse reactions: GI irritation, esophageal inflammation/ulceration, osteonecrosis of the jaw (ONJ), and atypical femoral fractures with long-term use. ONJ is rare but serious; patients should have dental exams before starting therapy.
- Drug interactions: Antacids, calcium supplements, and iron all reduce bisphosphonate absorption. The drug must be taken on an empty stomach with plain water only, at least 30 minutes before any other food, drink, or medication.
Calcium preparations (calcium carbonate, calcium citrate)
- Indications: Prevention and treatment of osteoporosis, supplementation for inadequate dietary intake
- Adverse reactions: Constipation, gas, bloating; rarely hypercalcemia with excessive intake. Calcium carbonate requires stomach acid for absorption, so calcium citrate is the better choice for patients on proton pump inhibitors or with low stomach acid.
- Drug interactions: Calcium can decrease absorption of bisphosphonates, tetracyclines, and fluoroquinolones. Space calcium at least 2 hours apart from these medications.
Vitamin D (cholecalciferol, calcitriol)
- Indications: Prevention and treatment of osteoporosis, vitamin D deficiency
- Adverse reactions: Hypercalcemia, hypercalciuria, and rarely nephrocalcinosis (calcium deposits in the kidneys) at high doses
- Drug interactions: Thiazide diuretics reduce renal calcium excretion, which combined with vitamin D supplementation can increase the risk of hypercalcemia. Monitor serum calcium levels in patients on both.
Estrogen receptor modulators (raloxifene)
- Indications: Prevention and treatment of postmenopausal osteoporosis
- Adverse reactions: Hot flashes, leg cramps, and increased risk of venous thromboembolism (VTE) including deep vein thrombosis and pulmonary embolism. This is the most serious risk to watch for.
- Drug interactions: Cholestyramine and colestipol significantly decrease raloxifene absorption. If both are prescribed, administer them at different times.
Nursing care plan for patients taking osteoporosis medications
Assessment
- Evaluate risk factors: age, female sex, family history, low body weight, smoking, alcohol use, prolonged corticosteroid use, and history of fragility fractures
- Obtain baseline BMD using a DEXA scan to guide treatment decisions. A T-score of or lower indicates osteoporosis.
- Review current medications for potential interactions and assess for contraindications (e.g., esophageal disorders for bisphosphonates, history of VTE for raloxifene)
Interventions
- Administer medications as prescribed with attention to proper timing and technique, especially for bisphosphonates
- Encourage adequate calcium intake (1,000–1,200 mg/day for most adults) and vitamin D intake (600–800 IU/day, though many patients need more) through diet and supplements
- Promote weight-bearing exercise (walking, jogging, resistance training) and fall prevention strategies (home safety assessment, balance training, vision checks)
- Provide clear patient education on medication use, expected timeline for results, lifestyle modifications, and side effects to report
Monitoring
- Reassess BMD with DEXA scans typically every 1–2 years to evaluate treatment response
- Monitor serum calcium, phosphate, and 25-hydroxyvitamin D levels to avoid deficiency or toxicity
- Watch for signs of adverse reactions: GI discomfort or difficulty swallowing (bisphosphonates), jaw pain or loose teeth (ONJ), new thigh or groin pain (atypical fracture), and leg swelling or sudden shortness of breath (VTE with raloxifene)
- Evaluate medication adherence at each visit and address barriers such as cost, side effects, or confusion about administration
Patient education materials on osteoporosis medications
Proper administration
- Bisphosphonates: Take first thing in the morning on an empty stomach with a full glass (6–8 oz) of plain water only. Do not lie down for at least 30 minutes after taking the medication (60 minutes for ibandronate). Do not eat, drink anything else, or take other medications during this waiting period. This prevents esophageal irritation.
- Calcium and vitamin D: Take as directed, with or without food. Do not exceed the recommended dose. If taking more than 500 mg of calcium at once, split doses for better absorption.
- Raloxifene: Take once daily with or without food. Report any signs of blood clots immediately: leg swelling, warmth or redness in the calf, chest pain, or sudden shortness of breath.
Lifestyle modifications
- Engage in regular weight-bearing and resistance exercises (walking, stair climbing, lifting weights) to stimulate bone formation
- Eat a balanced diet rich in calcium (dairy products, leafy greens, fortified foods) and vitamin D (fatty fish, egg yolks, fortified milk and cereals)
- Avoid smoking and limit alcohol to no more than one drink per day, as both weaken bones
- Implement fall prevention: remove loose rugs and clutter, install grab bars in bathrooms, ensure good lighting, and wear supportive, non-slip shoes
Side effects to report
- Bisphosphonates: Difficulty swallowing, chest pain, or heartburn that doesn't resolve (esophageal irritation); jaw pain, swelling, or loose teeth (ONJ); new or unusual pain in the thigh or groin (atypical fracture)
- Calcium and vitamin D: Persistent constipation, nausea, excessive thirst, or frequent urination (possible hypercalcemia)
- Raloxifene: Calf pain, swelling, or warmth; chest pain or sudden shortness of breath (possible VTE); severe headache or vision changes
- Remind patients that reporting side effects early allows for timely adjustments to their treatment plan